
Several single center studies have provided evidence of immune zzso and zzso activity of therapeutic vaccination with zzso cells zzso in patients with zzso zzso The efficacy of this approach in patients with favorable prognosis zzso melanoma limited to the skin, subcutaneous zzso and lung zzso zzso zzso zzso was tested in a zzso two stage phase 2 study with zzso DC zzso 

The vaccine zzso consisted 8 doses of zzso zzso matured DC generated in zzso medium with zzso zzso colony stimulating factor zzso and zzso zzso zzso with zzso of three zzso melanoma cell lines, and matured with zzso zzso The primary zzso was zzso zzso 

Among 33 patients who received zzso there was one complete response zzso two partial responses zzso and six patients had stable disease zzso lasting more than eight zzso The overall zzso defined tumor growth control rate was zzso zzso confidence zzso of zzso zzso administration had minimal toxicity and it resulted in a high frequency of immune zzso to zzso melanoma zzso as assessed by in zzso immune monitoring zzso 

The administration of matured DC loaded with tumor zzso has significant zzso and zzso activity in patients with limited zzso zzso 

zzso 

